Manager TitleAgeSince
Chief Executive Officer - 26/08/2024
Corporate Secretary - 26/08/2024
Director TitleAgeSince
Chairman - 26/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/24 A Issuer sale

Director

976 0.0142%
8/26/24 A Issuer sale

Chief Administrative Officer

20,256 0.2954%
8/26/24 A Issuer sale

Chief Financial Officer

20,080 0.2929%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.42% - - 10.43M
+0.88%+1.18%+40.64%+74.91% 64.69B
+0.20%+7.51%+10.41%+78.36% 54.78B
+0.46%+3.10%+9.26%+100.13% 53.49B
+0.24%+5.43%+28.92%+52.00% 45.98B
-0.82%+1.05%+18.58%+125.54% 42.94B
-1.09%+1.79%+219.73%+831.24% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.71%+17.51%+59.73%+47.29% 23.67B
Average +1.08%+2.22%+47.70%+150.57% 42.57B
Weighted average by Cap. +0.70%+2.59%+44.89%+152.01%
Logo Agile Therapeutics, Inc.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
Employees
19
  1. Stock Market
  2. Stocks
  3. AGRX Stock